Tamas Hickish

23.7k total citations · 5 hit papers
145 papers, 13.5k citations indexed

About

Tamas Hickish is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Tamas Hickish has authored 145 papers receiving a total of 13.5k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Oncology, 55 papers in Pulmonary and Respiratory Medicine and 31 papers in Pathology and Forensic Medicine. Recurrent topics in Tamas Hickish's work include Colorectal Cancer Treatments and Studies (45 papers), Cancer Treatment and Pharmacology (41 papers) and Gastric Cancer Management and Outcomes (28 papers). Tamas Hickish is often cited by papers focused on Colorectal Cancer Treatments and Studies (45 papers), Cancer Treatment and Pharmacology (41 papers) and Gastric Cancer Management and Outcomes (28 papers). Tamas Hickish collaborates with scholars based in United Kingdom, Spain and United States. Tamas Hickish's co-authors include C. Topham, Thierry André, Josep Tabernero, C. Boni, Aimery de Gramont, David Cunningham, Matilde Navarro, John Bridgewater, Philip R. Clingan and Marta Zaninelli and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Tamas Hickish

142 papers receiving 13.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

2004 2.7k citations Thierry André, C. Boni et al. profile →
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

2009 1.6k citations Thierry André, C. Boni et al. Journal of Clinical Oncology profile →
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1998 973 citations David Cunningham, Tamas Hickish et al. The Lancet profile →
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

2013 774 citations Andreas Schneeweiß, Stephen Chia et al. Annals of Oncology profile →
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1997 691 citations Andrew Webb, David Cunningham et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tamas Hickish United Kingdom	45	10.2k	4.3k	3.1k	2.3k	1.9k	145	13.5k
Timothy Price Australia	48	10.7k 1.1×	5.0k 1.2×	2.8k 0.9×	3.1k 1.4×	2.3k 1.2×	476	14.8k
Donna Hollis United States	55	5.9k 0.6×	4.6k 1.1×	3.0k 1.0×	1.1k 0.5×	1.5k 0.8×	154	11.4k
Stefano Cascinu Italy	63	11.2k 1.1×	7.3k 1.7×	3.4k 1.1×	2.6k 1.1×	3.4k 1.8×	648	18.3k
David P. Kelsen United States	72	8.9k 0.9×	6.3k 1.5×	4.2k 1.4×	1.4k 0.6×	1.9k 1.0×	292	14.6k
George Fountzilas Greece	54	7.7k 0.8×	3.7k 0.9×	2.3k 0.7×	1.7k 0.7×	2.1k 1.1×	576	12.8k
Axel Grothey United States	57	14.2k 1.4×	4.9k 1.1×	3.5k 1.1×	3.9k 1.7×	2.5k 1.3×	331	18.6k
Bruno Vincenzi Italy	55	6.2k 0.6×	3.2k 0.7×	1.6k 0.5×	1.2k 0.5×	2.0k 1.0×	428	11.0k
Nicholas J. Petrelli United States	56	10.8k 1.1×	4.0k 0.9×	6.0k 1.9×	3.3k 1.4×	2.1k 1.1×	301	16.6k
Emilio Bajetta Italy	55	10.4k 1.0×	5.8k 1.4×	1.9k 0.6×	1.3k 0.6×	3.7k 1.9×	325	16.6k
Fausto Petrelli Italy	50	5.9k 0.6×	3.2k 0.7×	2.3k 0.7×	1.2k 0.5×	1.7k 0.9×	280	9.1k

Countries citing papers authored by Tamas Hickish

Since Specialization

Citations

This map shows the geographic impact of Tamas Hickish's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tamas Hickish with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tamas Hickish more than expected).

Fields of papers citing papers by Tamas Hickish

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tamas Hickish. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tamas Hickish. The network helps show where Tamas Hickish may publish in the future.

Co-authorship network of co-authors of Tamas Hickish

This figure shows the co-authorship network connecting the top 25 collaborators of Tamas Hickish. A scholar is included among the top collaborators of Tamas Hickish based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tamas Hickish. Tamas Hickish is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hickish, Tamas, Ajay Mehta, Mei-Ching Liu, et al.. (2022). Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial. Breast Cancer Research and Treatment. 192(3). 593–602. 9 indexed citations

Pogue–Geile, Katherine L., Thierry André, Nan Song, et al.. (2019). Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction-benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer).. Journal of Clinical Oncology. 37(15_suppl). 3503–3503. 6 indexed citations

Kurzrock, Razelle, Tamas Hickish, Lucjan Wyrwicz, et al.. (2018). Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer. OncoImmunology. 8(3). 1551651–1551651. 39 indexed citations

Bridgewater, John, S. Pugh, Amy Whitehead, et al.. (2017). Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): Mature analysis of overall survival (OS) in the New EPOC randomised controlled trial. Annals of Oncology. 28. v162–v162. 3 indexed citations

Schneeweiß, Andreas, Stephen Chia, Tamas Hickish, et al.. (2017). Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. European Journal of Cancer. 89. 27–35. 165 indexed citations

Hickish, Tamas, Lucjan Wyrwicz, Tomasz Sarosiek, et al.. (2016). O-027 A pivotal phase 3 trial of MABp1 in advanced colorectal cancer. Annals of Oncology. 27. ii128–ii128. 3 indexed citations

Hickish, Tamas, et al.. (2014). A midline for oxaliplatin infusion: the myth of safety devices. BMJ Case Reports. 2014. bcr2014204360–bcr2014204360. 7 indexed citations

Schneeweiß, Andreas, Stephen Chia, Tamas Hickish, et al.. (2013). Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Annals of Oncology. 24(9). 2278–2284. 774 indexed citations breakdown →

Schneeweiß, Andreas, Tamas Hickish, V. Harvey, et al.. (2011). S5-6: Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA).. Cancer Research. 71(24_Supplement). S5–6. 44 indexed citations

10.

Teixeira, Luís, Tamas Hickish, Christophe Tournigand, et al.. (2010). Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors.. Journal of Clinical Oncology. 28(15_suppl). 3524–3524. 5 indexed citations

11.

Chau, Ian, A. Norman, David Cunningham, et al.. (2009). The impact of primary tumour origins in patients with advanced oesophageal, oesophago–gastric junction and gastric adenocarcinoma—individual patient data from 1775 patients in four randomised controlled trials. Annals of Oncology. 20(5). 885–891. 40 indexed citations

12.

Chau, Ian, David Cunningham, Tamas Hickish, et al.. (2007). Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I–II study. Annals of Oncology. 18(4). 730–737. 31 indexed citations

13.

Ross, Paul J., David Cunningham, Alyson Norman, et al.. (2006). Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. European Journal of Cancer. 42(7). 827–834. 74 indexed citations

14.

Waters, Justin S., A. Norman, David Cunningham, et al.. (1999). Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. British Journal of Cancer. 80(1-2). 269–272. 221 indexed citations

15.

Hickish, Tamas, et al.. (1998). Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors. British Journal of Cancer. 78(1). 28–33. 52 indexed citations

16.

Nicolson, MC, et al.. (1997). Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy. British Journal of Cancer. 76(12). 1636–1639. 20 indexed citations

17.

Mattia, Elena Di, Silvia Chichiarelli, Tamas Hickish, et al.. (1997). Inhibition of in vitro proliferation of Epstein Barr Virus infected B cells by an antisense oligodeoxynucleotide targeted against EBV latent membrane protein LMP1. Oncogene. 15(4). 489–493. 12 indexed citations

18.

Eisen, Tim, Tamas Hickish, Ian E. Smith, John Sloane, & Suzanne A. Eccles. (1995). Small-cell lung cancer. The Lancet. 345(8960). 1285–1289. 7 indexed citations

19.

Powles, T.J., Tamas Hickish, Andreas Makris, et al.. (1995). Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.. Journal of Clinical Oncology. 13(3). 547–552. 267 indexed citations

20.

Hickish, Tamas, et al.. (1989). Experience with intermediate-dose (110?120 mg/m2) epirubicin. Cancer Chemotherapy and Pharmacology. 24(1). 61–4. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact